Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Yoshihiko Fukukura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6341-1462; OpenAlex author ID A5055550613. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 16

  1. Characteristics of ill-demarcated small pancreatic ductal adenocarcinoma on MRI: a multi-institutional retrospective cohort study. First author DOI 10.1007/s11604-026-02003-8↗
  2. Effective Extracellular Volume Fraction Determined by Equilibrium Contrast-Enhanced CT for Differentiating Autoimmune Pancreatitis from Pancreatic Ductal Adeno… First author DOI 10.3390/diagnostics15151845↗
  3. Value of Dual-Energy Computed Tomography for Detecting Small Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002207↗
  4. Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal … Co-author DOI 10.1016/j.ejrad.2021.110036↗
  5. Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.20.25430↗
  6. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal ade… Co-author DOI 10.1007/s00330-019-06517-w↗
  7. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.009↗
  8. Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic a… Co-author DOI 10.1007/s00330-018-5570-4↗
  9. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreati… Co-author DOI 10.1097/mpa.0000000000001427↗
  10. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT. Co-author DOI 10.1007/s00261-016-0987-1↗
  11. Computed diffusion-weighted MR imaging for visualization of pancreatic adenocarcinoma: Comparison with acquired diffusion-weighted imaging. Co-author DOI 10.1016/j.ejrad.2017.07.022↗
  12. Diffusion-weighted MR imaging of the pancreas: optimizing b-value for visualization of pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-015-4174-5↗
  13. Histogram Analysis of Apparent Diffusion Coefficient in Differentiating Pancreatic Adenocarcinoma and Neuroendocrine Tumor. First author DOI 10.1097/md.0000000000002574↗
  14. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000362↗
  15. Contrast-enhanced CT and diffusion-weighted MR imaging: performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejrad.2013.12.016↗
  16. Pancreatic adenocarcinoma: variability of diffusion-weighted MR imaging findings. Co-author DOI 10.1148/radiol.120111222↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takashi Yoshiura · 11 shared papers, 2016–2022 · strength 1.10
  2. Kosei Maemura · 5 shared papers, 2015–2020 · strength 0.46
  3. Yosuke Fujisaki · 3 shared papers, 2021–2022 · strength 0.42
  4. Shinya Nakamura · 3 shared papers, 2021–2022 · strength 0.42
  5. Shiho Arima · 3 shared papers, 2019–2020 · strength 0.33
  6. Masatoyo Nakajo · 3 shared papers, 2017–2020 · strength 0.29
  7. Keitaro Sofue · 1 shared paper, 2026 · strength 0.26
  8. Yoshiki Asayama · 1 shared paper, 2026 · strength 0.26
  9. Nobuhiro Fujita · 1 shared paper, 2026 · strength 0.26
  10. Dai Inoue · 1 shared paper, 2026 · strength 0.26
  11. Yoshifumi Noda · 1 shared paper, 2026 · strength 0.26
  12. Shogo Takeuchi · 1 shared paper, 2026 · strength 0.26
  13. Satoshi Goshima · 1 shared paper, 2026 · strength 0.26
  14. Akihiko Kanki · 1 shared paper, 2025 · strength 0.26
  15. Tsutomu Tamada · 1 shared paper, 2025 · strength 0.26
  16. Hiroaki Nagano · 2 shared papers, 2020–2021 · strength 0.23
  17. Toshikazu Shindo · 4 shared papers, 2012–2017 · strength 0.22
  18. Shinichi Hashimoto · 2 shared papers, 2015–2022 · strength 0.19
  19. Michiyo Higashi · 3 shared papers, 2014–2019 · strength 0.18
  20. Hiroshi Kurahara · 1 shared paper, 2022 · strength 0.15
  21. Dominik Marcel Nickel · 1 shared paper, 2021 · strength 0.15
  22. Masayuki Nakajo · 2 shared papers, 2012–2017 · strength 0.11
  23. Akihiro Tateyama · 2 shared papers, 2012–2014 · strength 0.08
  24. Suguru Yonezawa · 1 shared paper, 2015 · strength 0.04
  25. Yuko Mataki · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.